Critical Medicine Shortages – A Growing Concern For The EMA

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

During its meeting in March 2023, the Management Board of the European Medicines Agency (EMA) gave an update on the continued efforts of the agency’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to further monitor a number of serious medication shortages in the European Union and European Economic Area (EEA), especially those involving drugs containing the antibiotic amoxicillin.

The previous board meeting was centred on the MSSG asking EU Member States to examine national regulatory flexibilities to allow the distribution of medications that may not be permitted in their respective countries. In addition, the MSG reviewed ways to reduce antibiotic shortages for the next autumn as well as the winter season.

A new executive body, the Medical Devices Shortages Steering Group, convened for the first time on March 15 to coordinate urgent actions across the EU linked to the management of supply-and-demand difficulties of important medical equipment during public health emergencies.

The board was also updated on the Heads of Medicines Agencies (HMA)/EMA multi-stakeholder shortage workshop, which took place on March 1 and March 2. Around 300 participants discussed the work of the HMA/EMA Task Force on drug shortages and availability, offered updates on ongoing activities in the field, and reaffirmed a strong commitment to collaborate in the future to prevent shortages.

The Board also reviewed the EMA’s annual report for 2022, which revealed that the EMA recommended 89 medicines for human use, 41 of which contained new active substances, including the first gene therapy for the medication of severe but also moderately severe hemophilia B and the first medicine for the prevention of respiratory syncytial virus (RSV) lower airway disease in babies and young children.

Latest stories

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back